Effect of Pitavastatin and EPA on coronary artery calcification detected by computed tomography.

Effect of Pitavastatin and EPA on coronary artery calcification detected by computed tomography. - PEACH trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003171

Enrollment

240

Registered

2010-03-01

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with dyslipidemia and with coronary artery calcification.(Agatston score 1-999) (Patient of primary prevention of coronary heart disease)

Interventions

Pitavastatin 2mg Pitavastatin 4mg Pitavastatin 2mg and EPA 1800mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Dyslipidemia patient defined by guidline, or already treated by anti-dyslipidemia drugs. 2)Patient without recived PCI and CABG 3)Patient coronary CT within two months., And detected coronary artery calcification(Agatston score 1-999). 4)Over 20 years old.

Exclusion criteria

Exclusion criteria: 1)Patient with PCI or CABG. 2)Patient can't obtained clear CT image. 3Patient without coronary artery calcification(Agatsuton score=0) 4)Patient with heaviry-calcification on coronary artery (Agatston score >=1000) 5)Patient who are favorite to treat with anti-dyslipidemia drugs other than statin. 6)Famirial hypercholesterolemia. 7)Patient corresponded contraindication of Pitavastatin. 8)Patient considered to be improper to this trial by attending doctor.

Design outcomes

Primary

Measure	Time frame
The effect of Pitavastatin on coronary calcification score. (compariosn with highdose treatment and combination with EPA)	—

Secondary

Measure	Time frame
1) The ratio of achivement of LDL-C level on Guidline. 2) Changes in TC, LDL-C, TG, HDL-C, adiponectin, fatty asid furaction, RLP-C, subfraction of HDL, hs-CRP, MCP-1, Oxdative LDL, Quantification of CD34, RBC, WBC, Hb, Ht, platelate, BNP, creatinin, BUN, uricacid, total bilirubin, AST, ALT, gamma-GTP, CK(CPK), LDH, serum Na, serum K, serum Cl, FBS, fasting insulin 3)The ratio of MACCE 4)The ratio of adverse effect 5)The relation between clinical parameter and coronary calcification score, relation between clinical parameter and ratio of MACCE.	—

Measure

Time frame

1) The ratio of achivement of LDL-C level on Guidline. 2) Changes in TC, LDL-C, TG, HDL-C, adiponectin, fatty asid furaction, RLP-C, subfraction of HDL, hs-CRP, MCP-1, Oxdative LDL, Quantification of CD34, RBC, WBC, Hb, Ht, platelate, BNP, creatinin, BUN, uricacid, total bilirubin, AST, ALT, gamma-GTP, CK(CPK), LDH, serum Na, serum K, serum Cl, FBS, fasting insulin 3)The ratio of MACCE 4)The ratio of adverse effect 5)The relation between clinical parameter and coronary calcification score, relation between clinical parameter and ratio of MACCE.

—

Countries

Japan

Contacts

Public ContactKunihisa Kohno

Okayama Univesity hospital Department of Cardiovascular Medicine

kunihisakohno@msn.com086-235-7351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026